SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-288493
Filing Date
2020-11-09
Accepted
2020-11-09 07:33:53
Documents
6
Period of Report
2020-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d817404d8k.htm 8-K 31579
2 EX-3.1 d817404dex31.htm EX-3.1 7191
3 EX-5.1 d817404dex51.htm EX-5.1 6754
4 EX-99.1 d817404dex991.htm EX-99.1 59944
5 GRAPHIC g817404g81e36.jpg GRAPHIC 10625
6 GRAPHIC g817404sh.jpg GRAPHIC 8544
  Complete submission text file 0001193125-20-288493.txt   128308
Mailing Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140
Business Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 201296108
SIC: 2834 Pharmaceutical Preparations